Abstract
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Juvenile idiopathic arthritis is a systemic inflammatory disease that, if not well treated, leads to progressive irreversible changes not only in the musculoskeletal system.
In the recent decades, treatment options of JIA patients have improved significantly, mainly due the introduction of new modern biological drugs. However, conventional synthetic disease modifying anti-rheumatic drugs, especially methotrexate, remain the gold standard and allow us to reach the disease inactivity in the majority of patients.
At present the aim of JIA treatment is to achieve a long-term remission of the disease and prevent irreversible changes, which makes it possible for most patients to live a normal life without limitation.
